Form 4 for LGND LIGAND PHARMACEUTICALS INC
Accepted 2026-03-13 00:00:00 ET · period of report 2026-03-11 · accession 0002001011-26-000026 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-03-13 | 2026-03-11 | LGND | Espinoza Octavio | CFO | M - OptEx | $92.65 | +2,405 | 24.1K | +11% | +$222.8K |
| D | 2026-03-13 | 2026-03-11 | LGND | Espinoza Octavio | CFO | S - Sale+OE | $225.00 | -3,057 | 21.0K | -13% | -$687.8K |
| D | 2026-03-13 | 2026-03-11 | LGND | Espinoza Octavio | CFO | M - OptEx | $0.00 | -2,405 | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-03-11 | M | A | 2,405 | $92.65 | 24,067 | D | — | — | (F1) The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 19, 2025, in accordance with Rule 10b5-1. |
| 2 | Common | Common Stock | 2026-03-11 | S | D | 3,057 | $225.00 | 21,010 | D | — | — | (F1) The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 19, 2025, in accordance with Rule 10b5-1. |
| 3 | Derivative | Employee Stock Option (right to buy) | 2026-03-11 | M | D | 2,405 | $0.00 | 0 | D | $92.65 · — to 2028-03-02 | 2,405 Common Stock | (F1) The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 19, 2025, in accordance with Rule 10b5-1. (F2) The stock option is fully vested and exercisable. |